Evaluation of Heart-type Fatty Acid-binding Protein in Early Diagnosis of Acute Myocardial Infarction

Mi-Gil Moon,1 Chang-Hwan Yoon,1,2 Kyunghoon Lee,3,4 Si-Hyuck Kang,1,2 Tae-Jin Youn,1,2 and In-Ho Chae1,2

1Cardiovascular Center, Seoul National University Bundang Hospital, Seongnam, Korea
2Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea
3Department of Laboratory Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
4Department of Laboratory Medicine, College of Medicine, Seoul National University, Seoul, Korea

ABSTRACT

Background: Although electrocardiography and cardiac troponin play important roles in the diagnosis of acute coronary syndrome (ACS), there remain unmet clinical needs. Heart-type fatty acid-binding protein (H-FABP) has been identified as an early diagnostic marker of acute myocardial infarction (AMI). In this study, we examined the diagnostic and prognostic value of H-FABP in patients suspected with ACS.

Methods: We conducted an observational single-center cohort study, including 89 adults aged 30 years or older, who presented to the emergency room (ER) within 24 hours after the onset of chest pain and/or dyspnea. We performed laboratory analysis and point-of-care testing (POCT) for cardiac markers, including H-FABP, troponin I, and creatine kinase-myocardial band. We also evaluated the correlation between cardiac markers and left ventricular (LV) dysfunction and extent of coronary artery disease (CAD).

Results: In patients presented to ER within 4 hours after symptom onset (n = 49), the diagnostic accuracy of H-FABP for AMI, as quantified by the area under the receiver operating characteristic curve, was higher (0.738; 95% confidence interval [CI], 0.591–0.885) than other cardiac markers. In POCT, the diagnostic accuracy of H-FABP (56%; 95% CI, 45–67) was significantly higher than other cardiac markers. H-FABP was correlated with not extent of CAD but post-AMI LV dysfunction.

Conclusion: H-FABP is a useful cardiac marker for the early diagnosis of AMI and prediction of myocardial injury. Difference in the circulatory release timeline of cardiac markers could explain its utility in early-stage of myocardial injury.

Keywords: Heart-type Fatty Acid-binding Protein; Cardiac Troponin I; Creatinine Kinase-myocardial Band; Acute Myocardial Infarction

INTRODUCTION

Acute myocardial infarction (AMI) remains the leading cause of mortality and morbidity worldwide. For reducing mortality and improving prognosis, the rapid and accurate diagnosis of AMI is important, and medical treatment, including revascularization, is crucial at the appropriate time.1,3 Electrocardiogram (ECG) and cardiac troponin (cTn) play critical...
Usefulness of H-FABP in Early AMI Diagnosis

roles in the diagnosis and prognosis of AMI.4-6 Especially in patients without definite ECG changes, cTn has a major role in the diagnosis of acute coronary syndrome (ACS), and recent use of the high-sensitive cardiac troponin (hs-cTn) assay enables rapid diagnosis and provides higher accuracy than conventional cTn assays.2,3,7,8 Although the advent of hs-cTn has permitted an early diagnosis and the reliable ‘rule out’ algorithm of AMI, unmet clinical needs remain as cTn can be detected only after myocardial necrosis occurs with a delay of a few hours.2,6,9

Heart-type fatty acid-binding protein (H-FABP) is a small cytoplasmic protein involved in the transport of fatty acid in cardiomyocytes.10-12 It is mainly present in the myocardium and, following myocardial injury, it is rapidly released from the cytosol into circulation.11,12 After identification as an early diagnostic marker of AMI,13,14 H-FABP has been recognized as a prognostic marker, predicting long-term mortality in patients with ACS along with troponin, highly sensitive C-reactive protein, and B-type natriuretic peptide.15,16 However, as mentioned above, the evidence for the early diagnostic and prognostic value of the hs-cTn test is accumulating, the question remains whether additional new cardiac markers such as H-FABP are needed.2,17 Subsequent studies have demonstrated that H-FABP has additional prognostic value in addition to hs-cTn in patients with suspected ACS, but no additional diagnostic value.18-20 Another study has reported that the sensitivity and specificity of H-FABP are higher than hs-cTn within 2 hours from the onset of chest pain, and it could serve as an early diagnostic marker.21

In this study, we examined the diagnostic and prognostic value of H-FABP in patients with suspected ACS who visited the emergency room (ER), using both laboratory analysis and point-of-care testing (POCT).

METHODS

Study design
This observational single-center cohort study was conducted at the Seoul National University Bundang Hospital (SNUBH) from August 2018 until June 2019. The equipment for laboratory analysis and POCT was provided by Genematrix Inc. (Seongnam, Republic of Korea). The company and institute were not involved in the data collection, analysis, or writing of the manuscript, but were provided the opportunity to review the final manuscript version before submission.

Study population
In this study, the patients were 30 years of age or older and presented to the ER within 24 hours following the onset of chest pain and/or dyspnea. Additionally, to be eligible for study inclusion, patients had to be referred for suspected ACS and agree to participate in the study. Exclusion criteria were as follows: 1) decreased consciousness and/or neurological abnormalities; 2) comorbidities other than ACS that require hospital admission; 3) presentation to the ER out of the working hours of laboratory for H-FABP; 4) diagnosis and treatment for malignant neoplasm; and 5) Creatinine clearance < 30 mL/min or a patient undergoing dialysis.

The enrolled patients were divided into two groups. One group visited the ER within 4 hours of the onset of chest pain and/or dyspnea; the other group visited the ER between 4 and 24 hours following the onset of symptoms. The number of subjects in each group was not predetermined.
Study protocol
At presentation, patients underwent routine clinical examination and a 12-lead ECG. The first venous blood sample was collected at the ER and used for both laboratory analysis and POCT of cardiac markers, including H-FABP, troponin I (TnI), and creatine kinase-myocardial band (CK-MB). The second and third venous samplings were performed for the serial laboratory analyses of cardiac markers. For each patient, the first, second, and third sampling times varied as the venous blood sampling interval was not fixed (Fig. 1).

Laboratory analysis of H-FABP was performed using a machine utilizing the domestically developed latex turbidimetric immunoassay (LTIA) method. POCT of cardiac markers was performed with rapid kits using a domestically developed immunochromatography (ICA) method. The laboratory results of each cardiac marker were reported within an hour. It took 10 to 15 minutes to obtain POCT result for each cardiac markers. Both laboratory analysis and POCT were performed by a blinded tester.

Study endpoint
The primary outcome was the diagnostic value of H-FABP in the early diagnosis of AMI, determined from the first venous sample at the ER. H-FABP was measured using both laboratory analysis and POCT and compared with other cardiac markers, including TnI and CK-MB. When diagnosing AMI with POCT, positive and negative values were visually judged. The fourth universal definition of myocardial infarction (MI) was utilized for assessments with laboratory analysis.6
The secondary outcome was the prognostic value of the cardiac markers in relation to left ventricular (LV) dysfunction and extent of coronary artery disease (CAD) using laboratory analysed results from 1st, 2nd, and 3rd venous samples. The degree of LV dysfunction was assessed with the left ventricular ejection fraction (LVEF) and wall motion score index (WMSI), which measured by transthoracic echocardiography performed after the ER visit. The extent of CAD was evaluated by coronary angiography (CAG), and significant lesion was defined as stenosis of > 50% of the reference coronary arterial diameter.

**Statistical analysis**

We presented continuous variables as mean ± standard deviation (SD) or median with interquartile range (IQR), and categorical variables as frequencies. For comparisons between two groups, the Student’s t-test and Mann-Whitney U test was performed for continuous variables, and χ² test and fisher’s exact test for categorical variables. To assess their diagnostic accuracy, receiver operating characteristic (ROC) curves were generated for each laboratory analysis of cardiac markers. Then, we compared the area under the ROC curve (AUC) value of H-FABP and TnI using Delong’s test. The confusion matrix and McNemar’s test were used to assess the POCT accuracy.

Kruskal-Wallis test with Bonferroni post-hoc analysis was used for multiple comparison. Spearman correlation analysis was used to examine relationship between cardiac markers and degree of LV dysfunction.

Statistical analyses were conducted using the R programming, version 4.0.2 (http://www.R-project.org; The R Foundation for Statistical Computing, Vienna, Austria). A P value < 0.05 was considered statistically significant.

**Ethics statement**

This investigation conformed to the principles outlined in the Declaration of Helsinki and the Institutional Review Board at SNUBH approved the study protocol (B-1702-382-301). Written informed consent was obtained from every patient at the point of inclusion in the study.

**RESULTS**

In total, 89 patients were included in the study. The baseline characteristics are summarized in Table 1. The mean age was 62.3 years, with more male than female patients included. As conventional cardiovascular risk factors, the occurrence of hypertension (HTN), diabetes mellitus (DM), dyslipidemia, and current smoking was 48.3%, 22.5%, 28.1%, and 38.2%, respectively. Additionally, 14 patients had previously received primary coronary interventions and 1 patient had undergone coronary artery bypass graft surgery.

Sixty-five patients were finally diagnosed with AMI, of which 37 patients were ST-elevation myocardial infarction (STEMI) and 28 patients were non-ST-elevation myocardial infarction (NSTEMI). There were five patients with unstable angina (UA), 17 patients with other cardiac disease, and two patients with non-cardiac disease. We compared the baseline characteristics according to whether diagnosed as AMI (Table 1). There was no difference in cardiovascular risk factors except cholesterol level which was higher in AMI patients. Non-AMI patients received more primary coronary interventions and had more atrial fibrillation.
We also compared baseline characteristics according to ER visit time. Forty-nine patients visited the ER within 4 hours after the onset of chest pain and/or dyspnea, and there was no significant difference between two groups.

Diagnostic accuracy of H-FABP vs. TnI and CK-MB using laboratory analysis

The diagnostic accuracy of cardiac markers for AMI in all patients is shown in the Fig. 2A. The AUC values of H-FABP, TnI, and CK-MB were 0.771 (95% confidence interval [CI], 0.674–0.868), 0.759 (95% CI, 0.664–0.854), and 0.690 (95% CI, 0.580–0.801), respectively. The AUC value of H-FABP was the highest, and statistically significant difference was not observed between H-FABP and TnI (P = 0.81, Delong’s test).

All patients included in this study were classified according to ER visit time after symptom onset. In the group presenting at the ER within 4 hours (n = 49), the AUC value of H-FABP for quantifying diagnostic accuracy was 0.738 (95% CI, 0.591–0.885). The AUC values of TnI and CK-MB were 0.667 (95% CI, 0.527–0.808) and 0.624 (95% CI, 0.459–0.790), respectively (Fig. 2B). Only the AUC value of H-FABP was above 0.7, without statistical difference with TnI (P = 0.37, Delong’s test). In the group presenting at the ER between 4 and 24 hours, the AUC values of H-FABP, TnI, and CK-MB were 0.835 (95% CI, 0.712–0.957), 0.883 (95% CI, 0.760–1.0), and 0.805 (95% CI, 0.671–0.939), respectively (Fig. 2C). No statistically significant difference was observed between H-FABP and TnI (P = 0.50, Delong’s test).

### Table 1. Baseline characteristics according to diagnosis of AMI and ER visit time

| Characteristics                  | All patients (n = 89) | Non-AMI patients (n = 24) | AMI patients (n = 65) | P value 0–4 hr (n = 49) | P value 4–24 hr (n = 40) |
|----------------------------------|----------------------|---------------------------|-----------------------|------------------------|------------------------|
| Age, yr                          | 62.3 ± 12.2          | 65.8 ± 12.3               | 61.0 ± 12.0           | 0.095                  | 61.8 ± 12.4            | 62.8 ± 12.2 | 0.714 |
| Sex, male                        | 63 (70.8)            | 14 (58.3)                 | 49 (75.4)             | 0.177                  | 34 (69.4)              | 29 (72.5)  | 0.748 |
| Chest pain onset                 |                      |                           |                       |                        |                        |            |      |
| 0–4 hr                           | 49 (55.1)            | 11 (45.8)                 | 38 (58.5)             | 0.288                  | -                      | -          |      |
| Grace score                      | 105.4 ± 30.9         | 104.8 ± 32.6              | 105.7 ± 30.6          | 0.907                  | 107.4 ± 33.4           | 103.0 ± 27.8 | 0.507 |
| Creatinine, mg/dL                | 0.9 ± 0.3            | 1.0 ± 0.5                 | 0.9 ± 0.3             | 0.941                  | 0.9 ± 0.3              | 0.8 ± 0.3 | 0.143 |
| Renal impairment                 | 11 (12.4)            | 4 (16.7)                  | 7 (10.8)              | 0.478                  | 6 (12.2)               | 5 (12.5)  | 1.000 |
| Hemoglobin, g/dL                 | 14.4 ± 1.8           | 13.8 ± 1.9                | 14.6 ± 1.7            | 0.083                  | 14.5 ± 1.7             | 14.3 ± 2.0 | 0.956 |
| Total cholesterol, mg/dL         | 172.7 ± 40.9         | 157.5 ± 38.4              | 178.4 ± 40.6          | 0.031                  | 180.1 ± 40.9           | 163.4 ± 39.1 | 0.057 |
| Risk factor                      |                      |                           |                       |                        |                        |            |      |
| HTN                              | 43 (48.3)            | 11 (45.8)                 | 32 (49.2)             | 0.775                  | 27 (55.1)              | 16 (40.0) | 0.156 |
| DM                               | 20 (22.5)            | 5 (20.8)                  | 15 (23.1)             | 0.822                  | 12 (24.5)              | 8 (20.0)  | 0.614 |
| Dyslipidemia                     | 25 (28.1)            | 8 (33.3)                  | 17 (26.2)             | 0.504                  | 17 (34.7)              | 8 (20.0)  | 0.125 |
| Smoking                          |                      |                           |                       | 0.056                  |                        |            |      |
| Current smoker                   | 34 (38.2)            | 5 (20.8)                  | 29 (44.6)             | 0.040                  | 20 (40.8)              | 14 (35.0) | 0.590 |
| Ex-smoker                        | 14 (15.7)            | 3 (12.5)                  | 11 (16.9)             | 0.822                  | 6 (12.2)               | 8 (20.0)  |      |
| Never-smoker                     | 41 (46.1)            | 16 (66.7)                 | 25 (38.5)             | 0.504                  | 23 (46.9)              | 18 (45)   |      |
| Family history of CAD            | 19 (21.3)            | 4 (16.7)                  | 15 (23.1)             | 0.513                  | 13 (26.5)              | 6 (15)    | 0.187 |
| Past history                     |                      |                           |                       |                        |                        |            |      |
| Previous PCI                     | 14 (15.7)            | 9 (37.5)                  | 5 (7.7)               | 0.002                  | 7 (14.3)               | 7 (17.5)  | 0.679 |
| Previous CABG                    | 1 (1.1)              | 0 (0)                     | 1 (1.5)               | 1.000                  | 1 (2.0)                | 0 (0)     | 1.000 |
| Previous PAD                     | 0 (0)                | 0 (0)                     | 0 (0)                 | -                      | 0 (0)                  | 0 (0)     |      |
| Electrocardiogram                |                      |                           |                       |                        |                        |            |      |
| ST-segment elevation             | 40 (44.9)            | 4 (16.7)                  | 36 (55.4)             | 0.001                  | 24 (49.0)              | 16 (40.0) | 0.397 |
| ST-segment depression            | 8 (9)                | 0 (0)                     | 8 (12.3)              | 0.102                  | 4 (8.2)                | 4 (10.0)  | 1.000 |
| T-wave inversion                 | 10 (11.2)            | 1 (4.2)                   | 9 (13.8)              | 0.276                  | 3 (6.1)                | 7 (17.5)  | 0.106 |
| Atrial fibrillation              | 4 (4.5)              | 4 (16.7)                  | 0 (0)                 | 0.004                  | 3 (6.1)                | 1 (2.5)   | 0.624 |
| RBBB                             | 4 (4.5)              | 0 (0)                     | 4 (6.2)               | 0.571                  | 2 (4.1)                | 2 (5.0)   | 1.000 |
| LBBB                             | 1 (1.1)              | 0 (0)                     | 1 (1.5)               | 1.000                  | 1 (2.0)                | 0 (0)     | 1.000 |

Values are presented as mean ± standard deviation, or number (%). Renal impairment was defined as eGFR lower than 50 mL/min/1.73 m².

ER = emergency room, AMI = acute myocardial infarction, HTN = hypertension, DM = diabetes mellitus, CAD = coronary artery disease, PCI = percutaneous coronary intervention, CABG = coronary artery bypass graft, PAD = peripheral artery disease, RBBB = right bundle branch block, LBBB = left bundle branch block, eGFR = estimated glomerular filtration rate.
We compared all cardiac marker levels according to ER visit time and final diagnosis (Table 2). Most cardiac markers did not show significant differences in the initial and second measurements according to the ER visit time, but the initial level of TnI was higher in patients visiting ER between 4 and 24 hours ($P = 0.01$, Mann-Whitney U test). In patients finally diagnosed with STEMI or NSTEMI, all cardiac markers were significantly higher than those diagnosed with UA or non-CAD. Fig. 3 shows serial changes in each cardiac marker levels after symptom onset. H-FABP was first detected within 2 to 3 hours after symptom onset, followed by TnI and CK-MB.

![Fig. 2. ROC curve describing the diagnostic accuracy of H-FABP (black line), TnI (red line), and CK-MB (blue line) for acute myocardial infarction. (A) All patients ($n = 89$). (B) Patients presenting at the emergency room within 4 hours after onset of chest pain and/or dyspnea ($n = 49$). (C) Patients presenting at the emergency room between 4 and 24 hours after onset of chest pain and/or dyspnea ($n = 40$). CI = confidence interval, ROC = receiver operating characteristic, AUC = area under the ROC curve, H-FABP = heart-type fatty acid-binding protein, TnI = troponin I, CK-MB = creatine kinase-myocardial band.]

| Cardiac marker | AUC (95% CI) |
|----------------|--------------|
| Plasma H-FABP  | 0.771 (0.674–0.759) |
| Plasma TnI     | 0.759 (0.664–0.854)  |
| Plasma CK-KB   | 0.690 (0.580–0.801)  |

| Cardiac marker | AUC (95% CI) |
|----------------|--------------|
| Plasma H-FABP  | 0.738 (0.591–0.885) |
| Plasma TnI     | 0.667 (0.527–0.808)  |
| Plasma CK-KB   | 0.624 (0.459–0.790)  |

| Cardiac marker | AUC (95% CI) |
|----------------|--------------|
| Plasma H-FABP  | 0.835 (0.712–0.957) |
| Plasma TnI     | 0.883 (0.760–1.000)  |
| Plasma CK-KB   | 0.805 (0.671–0.939)  |

**Fig. 3.** Changes over time in plasma H-FABP (green dot and line), TnI (blue dot and line), and CK-MB (red dot and line) after chest pain and/or dyspnea onset. H-FABP = heart-type fatty acid-binding protein, TnI = troponin I, CK-MB = creatine kinase-myocardial band.
Table 2. Level of cardiac markers according to emergency room visit time and final diagnosis

| Variables | Reference, ng/mL | All patients (n = 89) | ER visit time, hr | P value | Non-CAD (n = 19) | STEMI (n = 37) | NSTEMI (n = 28) | Unstable angina (n = 5) | P value |
|-----------|------------------|-----------------------|-------------------|---------|------------------|----------------|----------------|------------------------|---------|
|           |                  | 0–4 (n = 49)          | 4–24 (n = 40)     |         |                  |                |                |                        |         |
| 1st venous sampling |                  |                       |                   |         |                  |                |                |                        |         |
| H-FABP    | 0–5.0            | 2.90 (0.10–17.20)     | 1.80 (0.00–7.20)  | 6.52 (0.30–28.73) | 0.075 | 0.40 (0.10–2.10) | 5.80 (1.30–26.30) | 8.10 (0.65–26.48) | < 0.10 (< 0.10–< 0.10) | < 0.001 |
| Cardiac TnI | 0–0.045          | 0.07 (0.04–0.88)      | 0.00 (0.00–0.21)  | 0.25 (0.00–2.75)  | 0.007 | < 0.04 (0.04–0.05) | 0.09 (0.04–0.45) | 0.73 (0.06–4.27)  | < 0.04 (< 0.04–< 0.04) | < 0.001 |
| CK-MB     | 0–2.8            | 2.00 (1.00–8.40)      | 1.90 (0.00–3.40)  | 3.95 (1.15–12.35) | 0.058 | 1.30 (1.00–2.95) | 2.00 (1.19–8.60) | 6.15 (1.80–14.15) | < 1.00 (< 1.00–2.00) | 0.016  |
| 2nd venous sampling |                  |                       |                   |         |                  |                |                |                        |         |
| H-FABP    | 0–5.0            | 9.50 (0.20–28.20)     | 16.10 (1.20–31.70)| 5.00 (0.03–23.60)| 0.113 | < 0.10 (0.10–2.08)| 23.90 (12.20–55.00)| 12.00 (0.70–26.10)| < 0.10 (< 0.10–< 0.10)| < 0.001 |
| Cardiac TnI | 0–0.045          | 3.53 (0.07–31.60)     | 2.66 (0.12–40.00) | 5.10 (0.06–27.55)| 0.476 | < 0.04 (0.04–0.12)| 40.00 (12.40–105.00)| 2.27 (0.73–6.33) | < 0.04 (< 0.04–< 0.04) | < 0.001 |
| CK-MB     | 0–2.8            | 19.10 (1.81–86.40)    | 19.40 (2.30–101.80)| 14.40 (1.10–81.62)| 0.242 | 0.80 (1.00–2.33) | 101.80 (54.50–270.50)| 8.90 (3.15–22.15) | < 1.00 (< 1.00–1.30) | < 0.001 |

Values are presented as median (interquartile range).
H-FABP = heart-type fatty acid-binding protein, TnI = troponin I, CK-MB = creatine kinase-myocardial band.
Usefulness of H-FABP in Early AMI Diagnosis

Diagnostic accuracy of H-FABP vs. TnI and CK-MB by POCT
The diagnostic accuracy of H-FABP for AMI was 56% (95% CI, 45–67); for TnI and CK-MB, the diagnostic accuracies were 37% (95% CI, 27–48) and 35% (95% CI, 25–46), respectively. Hence, the accuracy of H-FABP and TnI differed significantly (P < 0.05).

Prognostic value of H-FABP vs. TnI and CK-MB
We evaluated the prognostic value of H-FABP in association with LV dysfunction and CAD extent, and compared it with TnI and CK-MB. All cardiac markers showed significant correlation with LV dysfunction, WMSI and LVEF. TnI and CK-MB showed correlation only in the second and third measurements, whereas H-FABP showed weak but significant correlation from the initial measurement (Fig. 4A and B).

A

![Graph](https://jkms.org)

B

![Graph](https://jkms.org)

Fig. 4. Relationship between cardiac markers and left ventricular dysfunction and extent of coronary artery disease with 1st, 2nd, and 3rd measurements. (A) Negative relationship between cardiac markers and LVEF. (B) Positive relationship between cardiac markers and WMSI. (C) Relationship between cardiac markers and coronary artery disease extent.

WMSI = wall motion score index, LVEF = left ventricular ejection fraction, H-FABP = heart-type fatty acid-binding protein, TnI = troponin I, CAD = coronary artery disease, CK-MB = creatine kinase-myocardial band, 1VD = 1 vessel disease, 2VD = 2 vessel disease, 3VD = 3 vessel disease.

(continued to the next page)
Usefulness of H-FABP in Early AMI Diagnosis

**DISCUSSION**

This observational study aimed to investigate the diagnostic and prognostic value of H-FABP in patients suspected with ACS. We hypothesized that H-FABP might be beneficial in the early diagnosis of AMI based on the different circulatory release times of cardiac markers following myocardial injury.\(^1\),\(^2\),\(^4\),\(^6\),\(^7\) The accuracy of H-FABP and TnI in the diagnosis of AMI using laboratory analysis demonstrated no statistical difference as quantified by the AUC values. However, patients who presented at the ER within 4 hours after symptom onset showed the

---

**Fig. 4.** (Continued) Relationship between cardiac markers and left ventricular dysfunction and extent of coronary artery disease with 1st, 2nd, and 3rd measurements. (A) Negative relationship between cardiac markers and LVEF. (B) Positive relationship between cardiac markers and WMSI. (C) Relationship between cardiac markers and coronary artery disease extent.

WMSI = wall motion score index, LVEF = left ventricular ejection fraction, H-FABP = heart-type fatty acid-binding protein, TnI = troponin I, CAD = coronary artery disease, CK-MB = creatine kinase-myocardial band, 1VD = 1 vessel disease, 2VD = 2 vessel disease, 3VD = 3 vessel disease.

Level of H-FABP was not relevant in predicting the extent of CAD, but showed significant difference between CAD and non-CAD (Fig. 4C). Levels of TnI and CK-MB also showed similar result.
highest diagnostic accuracy in H-FABP, while TnI demonstrated the highest diagnostic value in patients presenting between 4 and 24 hours, with no statistical significance observed. The rapid POCT kit for H-FABP demonstrated superior accuracy than TnI in the early-visit patients. Therefore, for physicians managing patients complaining of acute onset of chest pain and/or dyspnea, H-FABP could aid the rapid diagnosis of patients with ACS.

Although consensus on the diagnostic utility of H-FABP has not been established, some studies have suggested that H-FABP is useful in the early diagnosis of AMI. McCann et al.\textsuperscript{23} have analyzed 664 patients admitted to the cardiology department with acute chest pain for a duration of < 24 hours. They have observed that assessment of H-FABP within the first 4 hours of symptom onset is superior to cTn T for the detection of MI. In the present study, H-FABP was first detected within 2 to 3 hours following myocardial injury, followed by TnI and CK-MB (Fig. 3). Notably, as H-FABP is a small soluble protein, it is easily released into systemic circulation compared to other proteins. Its low threshold also attributes to early detection.

Kellens et al.\textsuperscript{24} have evaluated 203 patients referred for suspected ACS or presented at the ER with typical chest pain, using plasma high-sensitive troponin T (hs-TnT) and point-of-care H-FABP testing concomitantly performed at admission, and after 6 and 15 hours. For assessments performed within 3 hours of chest pain onset, the diagnostic accuracy of H-FABP and hs-TnT was comparable. In our study, POCT for H-FABP showed better diagnostic ability and convenience in performing and analyzing, thus it might be useful in early detection and exclusion of AMI at emergency medical service or ER.

We also evaluated the prognostic value of H-FABP. It was not relevant in predicting the extent of CAD, but helpful in predicting the extent of LV dysfunction after myocardial injury. Only initial level of H-FABP showed significant correlation with LVEF and WMSI although the correlation coefficient was very low. This is presumed to reflect H-FABP’s characteristic which being detected at early stage of myocardial injury.

This study has a few limitations. First, the number of enrolled patients was small. Second, there exists a selection bias. Registration was carried out in patients who were referred to cardiology department after primary emergency care, so patients presenting ER for dyspnea and/or chest pain were not consecutively collected. This resulted in an unbalanced distribution of data, with about 73% of patients finally diagnosed with AMI. Third, the interval between each venous sample was irregular. Because the consent was obtained after the diagnostic work-up and management were already conducted, we could not control the timing of blood collection.

In conclusion, H-FBAP is a useful cardiac marker for early diagnosis of AMI and prediction of myocardial injury. Differences in the circulatory release timeline of cardiac markers explain its utility in early stage of myocardial injury. Further large-scale clinical studies could help establish consensus regarding H-FABP test in Korea and compensate for the limitation of cTn test.

REFERENCES

1. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). \textit{Eur Heart J} 2018;39(2):119-77.
2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37(3):267-315. 
PUBMED | CROSSREF

3. Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. *N Engl J Med* 2009;361(9):858-67. 
PUBMED | CROSSREF

4. Savonitto S, Ardissino D, Granger CB, Morando G, Prando MD, Mafirici A, et al. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999;281(8):707-13. 
PUBMED | CROSSREF

5. Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. *N Engl J Med* 1996;335(18):1333-41. 
PUBMED | CROSSREF

6. Thygesen K. ‘Ten commandments’ for the fourth universal definition of myocardial infarction 2018. *Eur Heart J* 2019;40(3):226. 
PUBMED | CROSSREF

7. Reiter M, Twerebelold R, Reichlin T, Haaf P, Peter F, Meissner J, et al. Early diagnosis of acute myocardial infarction in the elderly using more sensitive cardiac troponin assays. *Eur Heart J* 2011;32(11):1379-89. 
PUBMED | CROSSREF

8. Twerebelold R, Jaffe A, Reichlin T, Reiter M, Mueller C. High-sensitive troponin T measurements: what do we gain and what are the challenges? *Eur Heart J* 2012;33(5):579-86. 
PUBMED | CROSSREF

9. Willeit P, Welsh EV, Evans JD, Tscherer B, Boachie C, Jukema JW, et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants. *J Am Coll Cardiol* 2017;70(5):558-68. 
PUBMED | CROSSREF

10. Glatz JF, van Bilsen M, Paulussen RJ, Veerkamp JH, van der Vusse GJ. Release of fatty acid-binding protein from isolated rat heart subjected to ischemia and reperfusion or to the calcium paradox. *Biochim Biophys Acta* 1988;961(1):148-52. 
PUBMED | CROSSREF

11. Tanaka T, Hirota Y, Sohmiya K, Nishimura S, Kawamura K. Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. *Clin Biochem* 1991;24(2):195-201. 
PUBMED | CROSSREF

12. Kleine AH, Glatz JF, Van Nieuwenhoven FA, Van der Vusse GJ. Release of heart fatty acid-binding protein into plasma after acute myocardial infarction in man. In: van der Vusse GJ, Stam H, editors. *Lipid Metabolism in the Healthy and Diseased Heart*. Boston, MA: Springer US; 1992, 155-62. 
PUBMED | CROSSREF

13. Seino Y, Ogata K, Takano T, Ishii J, Hishida H, Morita H, et al. Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: comparison with rapid troponin T and myoglobin tests. *Am J Med* 2003;115(3):185-90. 
PUBMED | CROSSREF

14. Okamoto F, Sohmiya K, Ohkami Y, Kawamura K, Asayama K, Kimura H, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. *Clin Chem Lab Med* 2000;38(3):231-8. 
PUBMED | CROSSREF

15. O’Donoghue M, de Lemos JA, Morrow DA, Murphy SA, Buros JL, Cannon CP, et al. Prognostic utility of heart-type fatty acid-binding protein in patients with acute coronary syndromes. *Circulation* 2006;114(6):590-7. 
PUBMED | CROSSREF

16. Kilcullen N, Viswanathan K, Das R, Morrell C, Farrin A, Barth JH, et al. Heart-type fatty acid-binding protein predicts long-term mortality after acute coronary syndrome and identifies high-risk patients across the range of troponin values. *J Am Coll Cardiol* 2007;50(21):2061-7. 
PUBMED | CROSSREF

17. Apple FS, Smith SW, Pearce LA, Murakami MM. Assessment of the multiple-biomarker approach for diagnosis of myocardial infarction in patients presenting with symptoms suggestive of acute coronary syndrome. *Clin Chem* 2009;55(1):93-100. 
PUBMED | CROSSREF

18. Reiter M, Twerebelold R, Reichlin T, Mueller M, Hoeller R, Moehring B, et al. Heart-type fatty acid-binding protein in the early diagnosis of acute myocardial infarction. *Heart* 2013;99(10):708-14. 
PUBMED | CROSSREF
19. Viswanathan K, Kilcullen N, Morrell C, Thistlethwaite SJ, Sivananthan MU, Hassan TB, et al. Heart-type fatty acid-binding protein predicts long-term mortality and re-infarction in consecutive patients with suspected acute coronary syndrome who are troponin-negative. *J Am Coll Cardiol* 2010;55(23):2590-8. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1016/j.jacc.2010.03.030)

20. Bank IE, Dekker MS, Hoes AW, Zuithoff NP, Verheggen PW, de Vrey EA, et al. Suspected acute coronary syndrome in the emergency room: limited added value of heart type fatty acid binding protein point of care or ELISA tests: the FAME-ER (Fatty Acid binding protein in Myocardial infarction Evaluation in the Emergency Room) study. *Eur Heart J Acute Cardiovasc Care* 2016;5(4):364-74. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1002/ejacc.1214)

21. Kitamura M, Hata N, Takayama T, Hirayama A, Ogawa M, Yamashina A, et al. High-sensitivity cardiac troponin T for earlier diagnosis of acute myocardial infarction in patients with initially negative troponin T test--comparison between cardiac markers. *J Cardiol* 2013;62(6):336-42. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1016/j.jjcc.2013.04.002)

22. Glatz JF, van der Vusse GJ, Simoons ML, Kragten JA, van Dieijen-Visser MP, Hermens WT. Fatty acid-binding protein and the early detection of acute myocardial infarction. *Clin Chim Acta* 1998;272(1):87-92. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1016/S0009-9147(98)00028-5)

23. McCann CJ, Glover BM, Menown IB, Moore MJ, McEneny J, Owens CG, et al. Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. *Eur Heart J* 2008;29(23):2843-50. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1093/eurheartj/ehn229)

24. Kellens S, Verbrugge FH, Vanmechelen M, Grieten L, Van Lierde J, Dens J, et al. Point-of-care heart-type fatty acid binding protein versus high-sensitivity troponin T testing in emergency patients at high risk for acute coronary syndrome. *Eur Heart J Acute Cardiovasc Care* 2016;5(2):177-84. [PUBMED](https://pubmed.ncbi.nlm.nih.gov) | [CROSSREF](https://doi.org/10.1002/ejacc.1172)